--- title: "FDA Expands Unannounced Foreign Inspections: How to Stay Inspection Ready" description: "FDA is expanding unannounced inspections at foreign sites. Learn how manufacturers can stay inspection ready through resilient systems, validated processes, and confident people." url: https://qbdgroup.com/en/blog/stay-inspection-ready-fda-foreign-inspections type: "Blog post" language: en published: 2025-10-01 author: "Dominiek Rossillion, Division Head Quality Assurance at QbD Group" category: "Qualification & Validation" publisher: "QbD Group" citation: "QbD Group, \"FDA Expands Unannounced Foreign Inspections: How to Stay Inspection Ready\", https://qbdgroup.com/en/blog/stay-inspection-ready-fda-foreign-inspections" --- # FDA Expands Unannounced Foreign Inspections: How to Stay Inspection Ready > FDA is expanding unannounced inspections at foreign sites. Learn how manufacturers can stay inspection ready through resilient systems, validated processes, and confident people. Since the FDA announced in May 2025 the expansion of **unannounced inspections at foreign manufacturing facilities,** a new regulatory landscape has emerged for companies supplying foods, essential medicines, and other medical products to the U.S. market. The shift brings global oversight into closer alignment with domestic practices—where surprise visits are already the norm—and aims to deter practices such as records falsification or “just-in-time” cleanups before an inspector arrives. This expanded approach builds on the agency’s earlier pilots in India and China and makes clear that **unannounced inspections are no longer the exception but increasingly the expectation** for foreign sites. Importantly, the FDA has also emphasized that it can take regulatory action against firms that **delay, deny, or limit inspections**, or refuse entry to investigators. ## Implications for Manufacturers and Site Leadership For companies manufacturing drug substances, drug products, biologics components, sterile packaging, excipients, or providing contract testing for U.S.-bound products, the reality is clear: **no advance notice should be expected.** The FDA highlights that U.S. manufacturers are frequently inspected without warning, and global suppliers are now expected to meet the same standard. With thousands of inspections conducted worldwide each year, and with data showing serious deficiencies more commonly identified at foreign sites, the agency’s push for parity signals both a higher likelihood of unannounced visits and deeper scrutiny of systems that cannot be staged, such as: - Data integrity - Staff training - Cross-functional compliance For site leadership, this shift means that **inspection readiness must become part of daily operations**, not an exercise triggered by preannounced visits. Systems like QMS, validation records, and data integrity controls must be consistently audit-ready, while staff at every level, from operators to QA reviewers, should be able to engage confidently with inspectors. Equally critical is the ability to **demonstrate digital compliance and cross-functional alignment.** Rapid record retrieval, defensible validation evidence, and seamless collaboration between QA, Regulatory, Pharmacovigilance, and IT will be decisive in avoiding findings. ## Best Practices to Stay Always Inspection Ready ### 1\. Conduct periodic gap assessments and mock inspections Test your systems under real conditions, starting from the reception desk to the shop floor. Simulate live document retrievals, floor walks, and cross-questioning to uncover weak spots before inspectors do. ### 2\. Strengthen your digital QMS and data integrity measures Ensure single-source-of-truth document control, validated reporting queries, and transparent audit trails. Periodic reviews should be up to date and demonstrate ALCOA+ principles in practice. ### 3\. Maintain robust validation packages From computerized systems (QMS, LIMS, MES, spreadsheets) to facilities, utilities, processes, and laboratory equipment, organizations should maintain clear, accessible validation evidence. This includes role-based access, backup/restore testing, and complete documentation ready for inspection. ### 4\. Prepare your people, not just your paperwork Train and coach staff so that SMEs, operators, and supervisors can answer confidently, reference procedures, and demonstrate compliance live without hesitation. ### 5\. Reinforce supplier and contract-lab oversight Inspectors often follow the paper trail. Quality agreements, audit results, and data transfers should show ongoing control, not one-off compliance. ### 6\. Integrate compliance across divisions Complaints, adverse events, labeling changes, CAPA, and software updates all connect. Seamless cross-functional visibility ensures no gaps are exposed when inspectors trace issues end-to-end. ## Final Thoughts The bottom line: FDA’s expanded use of unannounced inspections makes clear that **compliance cannot be staged.** Facilities that build continuous readiness into their culture, through resilient systems, validated processes, and confident people, will not only withstand regulatory scrutiny but also strengthen their operations every day. --- Source: https://qbdgroup.com/en/blog/stay-inspection-ready-fda-foreign-inspections — © QbD Group. Quote freely with attribution and a link back.